Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Amer H. Zureikat"'
Autor:
Louisa, Bolm, Martina, Nebbia, Alice C, Wei, Amer H, Zureikat, Carlos, Fernández-Del Castillo, Jian, Zheng, Alessandra, Pulvirenti, Ammar A, Javed, Yurie, Sekigami, Natalie, Petruch, Motaz, Qadan, Keith D, Lillemoe, Jin, He, Cristina R, Ferrone
Publikováno v:
Annals of surgery. 276(3)
The role of parenchyma-sparing resections (PSR) and lymph node dissection in small (3 cm) nonfunctional pancreatic neuroendocrine tumors (PNET) is unlikely to be studied in a prospective randomized clinical trial. By combining data from 4 high-volume
Autor:
Nathan Bahary, Naomi Fei, Rajesh Ramanathan, Melissa E. Hogg, Sijin Wen, Brian A. Boone, Herbert J. Zeh, Amer H. Zureikat, Aatur D. Singhi, Michael T. Lotze
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1822-1829 (2021)
Clinical and Translational Science
Clinical and Translational Science
SMAD4, a tumor suppressor gene, is lost in up to 60%–90% of pancreatic adenocarcinomas (PDAs). Loss of SMAD4 allows tumor progression by upregulating autophagy, a cell survival mechanism that counteracts apoptosis and allows intracellular recycling
Autor:
Henry A. Pitt, Mohamed A. Adam, Amblessed E. Onuma, Joal D. Beane, Amer H. Zureikat, Andrew Billderback, Jeffrey D. Borrebach
Publikováno v:
The American Journal of Surgery. 222:29-34
The aim of this analysis is to compare the postoperative outcomes of resection and enucleation of small pancreatic neuroendocrine tumors (PNETs).The 2014-17 American College of Surgeons-NSQIP dataset was queried. Patients undergoing pancreatoduodenec
Autor:
Alessandro Paniccia, Derek Barclay, Yoram Vodovotz, Jacob C. Hodges, Michael T. Lotze, Pranav Murthy, Amer H. Zureikat, Brian A. Boone, Randall E. Brand, Ruben Zamora, Kenneth K. Lee, Asmita Chopra, Richard L. Simmons
Publikováno v:
J Immunother
Despite its increased application in pancreatic ductal adenocarcinoma (PDAC), complete response to neoadjuvant therapy (NAT) is rare. Given the critical role of host immunity in regulating cancer, we sought to correlate baseline inflammatory profiles
Autor:
Jian, Zheng, Alessandra, Pulvirenti, Ammar A, Javed, Theodoros, Michelakos, Alessandro, Paniccia, Kenneth K, Lee, Cristina R, Ferrone, Alice C, Wei, Jin, He, Amer H, Zureikat
Publikováno v:
Journal of the American College of Surgeons. 235(2)
Resection of pancreatic neuroendocrine tumors (PNETs) may be associated with adverse perioperative outcomes compared with pancreatic adenocarcinoma given the high-risk nature of soft glands with small pancreatic ducts. The effect of minimally invasiv
Autor:
Brian A. Boone, Joal D. Beane, Mazen S. Zenati, Herbert J. Zeh, A. James Moser, Melissa E. Hogg, David L. Bartlett, Amr I. Al Abbas, Amer H. Zureikat
Publikováno v:
Ann Surg
OBJECTIVES: This study aims to present the outcomes of our decade-long experience of robotic pancreatoduodenectomy and provide insights into successful program implementation. BACKGROUND: Despite significant improvement inmortality over the past 30 y
Autor:
Deepa Magge, Amer H. Zureikat, Ahmad Hamad, Mazen S. Zenati, Herbert J. Zeh, Melissa E. Hogg, Caroline J. Rieser
Publikováno v:
HPB. 20:1172-1180
NSQIP data show that half of distal pancreatectomies (DP) are performed by a minimally invasive approach (MIS). Advantages have been demonstrated for MIS DP, yet comparative cost data are limited. Outcomes and cost were compared in patients undergoin
Publikováno v:
Journal of the National Comprehensive Cancer Network. 16:1424-1428
Gastrointestinal stromal tumors (GISTs) represent 1% of alimentary tract neoplasms. Up to 90% of GISTs are driven by activating mutations in tyrosine kinase KIT or PDGFRα genes. Imatinib mesylate is a tyrosine kinase inhibitor that has recently been
Publikováno v:
Annals of surgical oncology. 28(5)
Autor:
Samer Tohme, Sidrah Khan, Alison Althans, Maria Mascara, Richard S. Hoehn, Ibrahim Nassour, Amer H. Zureikat, Christof Kaltenmeier
Publikováno v:
Am Surg
Introduction With advances in multimodal therapy, survival rates in gastric cancer have significantly improved over the last two decades. Neoadjuvant therapy increases the likelihood of achieving negative margins and may even lead to pathologic compl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1ef003a121bec2ea08cc15d38edf601
https://europepmc.org/articles/PMC8213860/
https://europepmc.org/articles/PMC8213860/